Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
13 janv. 2025 09h00 HE
|
Apellis Pharmaceuticals, Inc.
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net...
Apellis Announces Keli Walbert to Join the Board of Directors
10 janv. 2025 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms....
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 janv. 2025 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 déc. 2024 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
27 nov. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: ...
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
12 nov. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
05 nov. 2024 07h05 HE
|
Apellis Pharmaceuticals, Inc.
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue...
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
26 oct. 2024 14h00 HE
|
Apellis Pharmaceuticals, Inc.
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan,...
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
22 oct. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third...